Cambridge, UK, 21 March 2019 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, announces winning the award for “Life Science Innovation” at the Business Weekly Awards 2019.
The “Life Science Innovation” award recognises “the organisation or individual who has done the most to further the cause of life science discovery for the benefit of human healthcare”.
Crescendo was recognized by the judging panel for a very successful year. The Company continued to build upon its highly productive multi-programme collaboration with Takeda, with two major technical milestones reached; Takeda also took an early licence to Humabodies directed to one of its oncology targets, validating Crescendo’s ability to deliver Humabody®-based therapeutic leads. In addition, Crescendo closed a $70m Series B in April 2018, attracting new top-tier investors from Europe and Asia. At the same time, the Company has formed a truly world class leadership team by hiring top-tier management and non-executive directors.
Dr Peter Pack, CEO of Crescendo Biologics commented: “We are extremely proud to have been awarded ‘Life Science Innovation’ at the Business Weekly Awards last night. It’s great to be recognised amongst the globally prestigious innovation hub of Cambridge. This is a testament to how well our team works together enabling so much success over the past 12 months.”
The Business Weekly Awards were held on Wednesday 20 March at Queens’ College, Cambridge, to celebrate the innovation cluster in Cambridge and the East of England.